credits bmbl December 7 '06.doc - Central Michigan University

More documents

Recommendations

Info

Agent Summary Statements – Bacterial Agents 79. Benin AL, Benson RF, Beser RE. Trends in legionnaires disease, 1980-1998: declining mortality and new patterns of diagnosis. Clin Infect Dis. 2002;35:1039- 46. 80. Yu VL, Plouffe JF, Pastoris MC, et al. Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis. 2002;186:127-8. 81. Fields BS, Benson RF, Besser RE. Legionella and legionaires’ disease: 25 years of investigation. Clin Microbiol Rev. 2002;15:506-26. 82. Centers for Disease Control and Prevention (CDC). 1976. Unpublished data. Center for Infectious Diseases. HEW, Public Health Service. 83. Friedman H, Yamamoto Y, Newton C, et al. Immunologic response and pathophysiology of Legionella infection. Semin Respir Infect. 1998;13:100-8. 84. Fabbi M, Pastoris MC, Scanziani E, et al. Epidemiological and environmental investigations of Legionella pneumophila infection in cattle and case report of fatal pneumonia in a calf. J Clin Microbiol. 1998;36:1942-7. 85. Muder RR, Yu VL, Woo A. Mode of transmission of Legionella pneumophila. A critical review. Arch Intern Med. 1986;146:1607-12. 86. Lowry PW, Tompkins LS. Nosocomial legionellosis: a review of pulmonary and extrapulmonary syndromes. Am J Infect Control. 1993;21:21-7. 87. Levett PN. Leptospira and Leptonema. In: Murray PR, Baron EJ, Jorgensen JH, et al, editors. Manual of clinical microbiology. 8 th ed. Washington, DC: ASM Press. 2003. p. 929-36. 88. Barkin RM, Guckian JC, Glosser JW. Infection by Leptospira ballum: a laboratory-associated case. South Med J. 1974;67:155 passim. 89. Bolin CA, Koellner P. Human-to-human transmission of Leptospira interrogans by milk. J Infect Dis. 1988;158:246-7. 90. Stoenner HG, Maclean D. Leptospirosis (ballum) contracted from Swiss albino mice. AMA Arch Intern Med. 1958;101:606-10. 91. Schuchat A, Swaminathan B, Broome CV. Epidemiology of human listeriosis. Clin Microbiol Rev. 1991;4:169-83. 92. Armstrong D. Listeria monocytogenes. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practices of infectious diseases. 4th ed. NY: Churchill Livingstone. 1995. p. 1880-85. 93. McLauchlin J, Low JC. Primary cutaneous listeriosis in adults: an occupational disease of veterinarians and farmers. Vet Rec. 1994;135:615-7. 94. Ortel S. Listeriosis during pregnancy and excretion of listeria by laboratory workers. Zentralbl Bakteriol [Orig. A]. 1975;231:491-502. 95. Centers for Disease Control and Prevention. Update: foodborne listeriosis-United States, 1988-1990. MMWR Morb Mortal Wkly Rep. 1992;41:251, 257-8. 96. Ryser ET, Marth EH, editors. Listeria, Listeriosis, and food safety. 2nd ed. New York: Marcel Dekker, 1999. 97. Gellin BG, Broome CV. Listeriosis. JAMA. 1989;261:1313-20. 98. Walsh GP, Storrs EE, Burchfield HP, et al. Leprosy-like disease occurring naturally in armadillos. J Reticuloendothel Soc. 1975;18:347-51. 99. Donham KJ, Leininger JR. Spontaneous leprosy-like disease in a chimpanzee. J Infect Dis. 1977;136:132-6. 180
Agent Summary Statements – Bacterial Agents 100. Meyers WM, Walsh GP, Brown HL, et al. Leprosy in a mangabey monkey-- naturally acquired infection. Int J Lepr Other Mycobact Dis. 1985;53:1-14. 101. Marchoux PE. Un cas d’inoculation accidentelle du bacilli de Hanson en pays non lepreux. Int J Lepr. 1934;2:1-7. 102. Parritt RJ, Olsen RE. Two simultaneous cases of leprosy developing in tattoos. Am J Pathol. 1947;23:805-17. 103. Grist NR, Emslie JA. Infections in British clinical laboratories, 1982-3. J Clin Pathol. 1985;38:721-5. 104. Muller HE. Laboratory-acquired mycobacterial infection. Lancet. 1988;2:331. 105. Pike RM, Sulkin SE, Schulze ML. Continuing importance of laboratory-acquired infections. Am J Public Health Nations Health. 1965;55:190-9. 106. Reid DD. Incidence of tuberculosis among workers in medical laboratories. Br Med J. 1957;(5035):10-4. 107. Kaufmann AF, Andersone DC. Tuberculosis control in nonhuman primates. In: Montali RJ, editor. Mycobacterial infections of zoo animals. Washington, DC: Smithsonian Institution Press. 1978. p. 227-34. 108. Allen BW. Survival of tubercle bacilli in heat-fixed sputum smears. J Clin Pathol. 1981;34:719-22. 109. Smithwick RW, Stratigos CB. Preparation of acid-fast microscopy smears for proficiency testing and quality control. J Clin Microbiol. 1978;8:110-1. 110. Oliver J, Reusser TR. Rapid method for the concentration of tubercle bacilli. Am Rev Tuberc. 1942;45:450-2. 111. Richmond JY, Knudsen RC, Good RC. Biosafety in the clinical mycobacteriology laboratory. Clin Lab Med. 1996;16:527-50. 112. Janda WM, Knapp JS. Neisseria and Moraxella catarrhalis. In: Murray PR, Baron EJ, Jorgensen JH, et al, editors. Manual of clinical microbiology. 8 th ed. Washington, DC: ASM Press. 2003. p. 585-608. 113. Diena BB, Wallace R, Ashton FE, et al. Gonococcal conjunctivitis: accidental infection. Can Med Assoc J. 1976;115:609-12. 114. Malhotra R, Karim QN, Acheson JF. Hospital-acquired adult gonococcal conjunctivitis. J Infect. 1998;37:305. 115. Bruins SC, Tight RR. Laboratory acquired gonococcal conjunctivitis. JAMA. 1979;241:274. 116. Zajdowicz TR, Kerbs SB, Berg SW, et al. Laboratory-acquired gonococcal conjunctivitis: successful treatment with single-dose ceftriaxone. Sex Transm Dis. 1984;11:28-9. 117. Centers for Disease Control and Prevention [www.cdc.gov]. Atlanta: The Centers; [updated 2006 April]. Gonorrhea – CDC Fact Sheet; [about five screens]. Available from: http://www.cdc.gov/std/Gonorrhea/STDFact-gonorrhea.htm 118. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-7):1-10. 119. Boutet R, Stuart JM, Kaczmarski EB, et al. Risk of laboratory-acquired meningococcal disease. J Hosp Infect. 2001;49:282-4. 120. Centers for Disease Control and Prevention. Laboratory-acquired meningococcal diseases--United States, 2000. MMWR Morb Mortal Wkly Rep. 2002;51:141-4. 181
Page 1 and 2:
Biosafety in Microbiological and Bi
Page 3 and 4:
SECTION VIII-H: Prion Diseases 299
Page 5 and 6:
Forward Biosafety in Microbiologica
Page 7 and 8:
Editors: L. Casey Chosewood, MD Dir
Page 9 and 10:
Guest Editors: Matthew J. Arduino,
Page 11 and 12:
Charles B. Millard, PhD Lieutenant
Page 13 and 14:
Robert Bull Karen B. Byers Jane Cap
Page 15 and 16:
Thomas L. Miller Douglas M. Moore M
Page 17 and 18:
Robert Yarchoan Uri Yokel Lisa Youn
Page 19 and 20:
Introduction laboratories chose not
Page 21 and 22:
Introduction RISK CRITERIA FOR ESTA
Page 23 and 24:
Introduction BMBL includes an impor
Page 25 and 26:
Section II Biological Risk Assessme
Page 27 and 28:
Biological Risk Assessment informat
Page 29 and 30:
Biological Risk Assessment The NIH
Page 31 and 32:
Biological Risk Assessment effectiv
Page 33 and 34:
Biological Risk Assessment Third, m
Page 35 and 36:
Biological Risk Assessment 14. Oxma
Page 37 and 38:
Principles of Biosafety Safety equi
Page 39 and 40:
Principles of Biosafety Often an in
Page 41 and 42:
Principles of Biosafety Four standa
Page 43 and 44:
Principles of Biosafety 4. Centers
Page 45 and 46:
Laboratory Biosafety Level Criteria
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Section V Vertebrate Animal Biosafe
Page 77 and 78:
Vertebrate Animal Biosafety Level C
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
TABLE 1 SUMMARY OF RECOMMENDED BIOS
Page 121 and 122:
Principles of Laboratory Biosecurit
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130: Principles of Laboratory Biosecurit
Page 131 and 132: Occupational Health and Immunoproph
Page 139 and 140: Agent Summary Statements - Bacteria
Page 179: Agent Summary Statements - Bacteria
Page 185 and 186: • Section VIII-B: Fungal Agents A
Page 187 and 188: Agent Summary Statements - Fungal A
Page 197 and 198: • Section VIII-C: Parasitic Agent
Page 199 and 200: Agent Summary Statements - Parasiti
Page 209 and 210: • Section VIII-D: Rickettsial Age
Page 211 and 212: Agent Summary Statements - Ricketts
Page 213 and 214: Agent Summary Statements - Ricketts
Page 215 and 216: • Section VIII-E: Viral Agents Ag
Page 217 and 218: Agent Summary Statements - Viral Ag
Page 231 and 232:
Agent Summary Statements - Viral Ag
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Agent Summary Statements - Arboviru
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
• Section VIII-G: Toxin Agents Se
Page 287 and 288:
Agent Summary Statements - Toxins i
Page 289 and 290:
Agent Summary Statements - Toxins A
Page 291 and 292:
Agent Summary Statements - Toxins L
Page 293 and 294:
Agent Summary Statements - Toxins e
Page 295 and 296:
Agent Summary Statements - Toxins o
Page 297 and 298:
Agent Summary Statements - Toxins t
Page 299 and 300:
• Section VIII-H: Prion Diseases
Page 301 and 302:
Agent Summary Statement - Prion Dis
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Appendix A Proper maintenance of ca
Page 309 and 310:
Appendix A declined. However, in ma
Page 311 and 312:
Appendix A It is possible to exhaus
Page 313 and 314:
Appendix A 4. The Class II, Type A2
Page 315 and 316:
Appendix A prohibited. Furthermore,
Page 317 and 318:
Appendix A plastic wrappers, pipett
Page 319 and 320:
Appendix A touch-plate microburners
Page 321 and 322:
Appendix A SECTION VI FACILITY AND
Page 323 and 324:
Appendix A Development of Containme
Page 325 and 326:
Appendix A C. Airflow Smoke Pattern
Page 327 and 328:
Appendix A TABLES Table 1. Selectio
Page 329 and 330:
Appendix A Table 3. Field Performan
Page 331 and 332:
Appendix A FIGURES Figure 1. HEPA f
Page 333 and 334:
Appendix A Figure 3. The Class II,
Page 335 and 336:
Appendix A Figure 5B. The Class II,
Page 337 and 338:
Appendix A Figure 8. The Class III
Page 339 and 340:
Appendix A Figure 9B. The vertical
Page 341 and 342:
Appendix A Figure 11. A typical lay
Page 343 and 344:
Appendix A REFERENCES 1. Centers fo
Page 345 and 346:
Appendix B Decontamination and Disi
Page 347 and 348:
Appendix B surfaces are contaminate
Page 349 and 350:
Appendix B TABLE 1 DESCENDING ORDER
Page 351 and 352:
Appendix B dioxide gas exits the ge
Page 353 and 354:
Appendix B d The effectiveness of a
Page 355 and 356:
Appendix C Transportation of Infect
Page 357 and 358:
Appendix C 1600 Clifton Road, N.E.,
Page 359 and 360:
Appendix C disease in humans or in
Page 361 and 362:
Appendix C Biological specimen, Cat
Page 363 and 364:
Appendix D Agriculture Pathogen Bio
Page 365 and 366:
Appendix D simultaneous opening of
Page 367 and 368:
Appendix D 14. Pathological inciner
Page 369 and 370:
Appendix D Wastes and other materia
Page 371 and 372:
Appendix D Camelpox virus b a, b, c
Page 373 and 374:
Appendix D SPECIAL ISSUES The impor
Page 375 and 376:
Appendix D required by the USDA and
Page 377 and 378:
Appendix D depression, anorexia, an
Page 379 and 380:
Appendix D laboratory with enhancem
Page 381 and 382:
Appendix D five day period of conta
Page 383 and 384:
Appendix D slaughterhouses or indus
Page 385 and 386:
Appendix D virus does not cause any
Page 387 and 388:
Appendix D NDV is classified in the
Page 389 and 390:
Appendix D movement permit is requi
Page 391 and 392:
Appendix D Spring Viremia of Carp V
Page 393 and 394:
Appendix D REFERENCES 1. Hess WR. A
Page 395 and 396:
Appendix D 37. Alexander DJ. Newcas
Page 397 and 398:
Appendix E Arthropod Containment Gu
Page 399 and 400:
Appendix F Select Agents and Toxins
Page 401 and 402:
Appendix G IPM issues and requireme
Page 403 and 404:
Appendix H Working with Human, NHP
Page 405 and 406:
Appendix I Guidelines for Work with
Page 407 and 408:
decontaminated periodically, for ex
Page 409 and 410:
0.25N, and/or sodium hypochlorite (
Page 411 and 412:
k Irradiation causes a dose-depende
Page 413 and 414:
7. Morin R, Kozlovac J. Biological
Page 415 and 416:
Appendix J NIH Oversight of Researc
Page 417 and 418:
Appendix K Resources for Informatio
Page 419 and 420:
Appendix K E-mail: http://www2.gsu.
Page 421 and 422:
Appendix K and http://www.who.int/c
Page 423 and 424:
Appendix L HEPA High Efficiency Par
show all

credits bmbl December 7 '06.doc - Central Michigan University

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?